Qiagen Downgraded by Investment Firm Macquarie

Macquarie cited competition and potential budget cuts in downgrading Qiagen's shares, lowering its revenue and EPS estimates, and pushing down its target share price.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories